about
Characterisation of the triple negative breast cancer phenotype associated with the development of central nervous system metastasesEffect of metamizol on promyelocytic and terminally differentiated granulocytic cells. Comparative analysis with acetylsalicylic acid and diclofenacComparison of prognostic gene profiles using qRT-PCR in paraffin samples: a retrospective study in patients with early breast cancerMALDI profiling of human lung cancer subtypes.Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics.PTRF/cavin-1 and MIF proteins are identified as non-small cell lung cancer biomarkers by label-free proteomics.PI3K/Akt signalling pathway and cancer.Implication of miRNA in the diagnosis and treatment of breast cancer.Identification and characterization of novel potentially oncogenic mutations in the human BAF57 gene in a breast cancer patient.MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.New insights in beta-tubulin sequence analysis in non-small cell lung cancer.Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications.Functional proteomics outlines the complexity of breast cancer molecular subtypes.Molecular characterization of breast cancer cell response to metabolic drugs.Probabilistic graphical models relate immune status with response to neoadjuvant chemotherapy in breast cancer.A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognosesMelanoma proteomics suggests functional differences related to mutational statusProlactin receptor is associated with c-src kinase in rat liverSrc family kinases are required for prolactin induction of cell proliferationComputational metabolism modeling predicts risk of distant relapse-free survival in breast cancer patientsIsotopologue Multipoint Calibration for Proteomics Biomarker Quantification in Clinical PracticeBiological molecular layer classification of muscle-invasive bladder cancer opens new treatment opportunitiesBayesian networks established functional differences between breast cancer subtypes
P50
Q26750508-0433244B-E7FE-4FB0-9F7A-39D988BB27B0Q28194528-9E62B4DE-0E9B-465D-88A3-635A3C2883A5Q33472698-34F4FC98-FD74-4756-8741-DA58918E75F7Q33515026-C105ACF0-03D4-413F-8D86-62818CC08096Q33778306-BBD31C65-B5DF-448B-88BC-00DF0D3F192FQ34213807-11B126BE-6392-4E04-8487-B7B89A39EBD7Q35692250-6CEFC379-0DCC-4AD2-8C35-66C07172A4FFQ37931898-4D101CBD-1EA6-4BBD-953A-55F7744892D8Q39564491-B681431D-E6CC-42D4-A9E5-7083C9327FDCQ40319760-36FD83B3-5A91-4C47-B62B-01CA1A5B6F9AQ40578959-28690302-53A3-4E16-AF83-75D32DE8A904Q41059996-95356743-428C-4111-AF77-A164E4576DB2Q41564586-287E0A44-0A38-45AA-A685-108B71275717Q52689272-BBE1A918-587A-44F3-A07C-65C0FF343460Q55357247-D207D9BD-8F59-47C2-A717-C722654A3172Q61798221-D8BCCBA3-9E38-45EC-87D8-B1284F172BE3Q64059069-E4E4551A-CF1F-43A1-A421-EE4D64A64455Q70957585-4F6D48CC-EFEB-4045-A72C-8BB6B5B57AD0Q74197200-89069D7D-D9B9-41F2-AFF4-536B00E83EFCQ90452666-714B705B-2442-48E4-A3A2-D4B6A3B54B68Q92434832-3E75CB21-18CB-4CDE-B71C-780118610FE0Q93111695-C8F279F2-B949-4866-8AA0-99AD34D72F5FQ96292013-540B5D02-F922-4C97-8DC5-13247E63494C
P50
description
researcher ORCID ID = 0000-0003-1527-1252
@en
wetenschapper
@nl
name
Juan Ángel Fresno Vara
@ast
Juan Ángel Fresno Vara
@en
Juan Ángel Fresno Vara
@es
Juan Ángel Fresno Vara
@nl
type
label
Juan Ángel Fresno Vara
@ast
Juan Ángel Fresno Vara
@en
Juan Ángel Fresno Vara
@es
Juan Ángel Fresno Vara
@nl
prefLabel
Juan Ángel Fresno Vara
@ast
Juan Ángel Fresno Vara
@en
Juan Ángel Fresno Vara
@es
Juan Ángel Fresno Vara
@nl
P106
P1153
6506686404
P21
P31
P4012
P496
0000-0003-1527-1252